Personalized medicine最新文献_第5页

Artificial intelligence in healthcare: a primer for medical education in radiomics. 医疗保健中的人工智能:放射组学医学教育入门。

IF 2.3 4区医学

Personalized medicine Pub Date : 2022-09-01 Epub Date: 2022-07-26 DOI: 10.2217/pme-2022-0014

Carly E Waldman, Melody Hermel, Jonathan A Hermel, Francis Allinson, Mark N Pintea, Natalie Bransky, Emem Udoh, Laura Nicholson, Austin Robinson, Jorge Gonzalez, Christopher Suhar, Keshav Nayak, George Wesbey, Sanjeev P Bhavnani

引用次数: 7

Analysis of pharmacogenomic very important pharmacogenomic variants: CYP3A5, ACE, PTGS2 and NAT2 genes in Chinese Bai population. 中国白族人群CYP3A5、ACE、PTGS2和NAT2基因的药物基因组学分析。

IF 2.3 4区医学

Personalized medicine Pub Date : 2022-09-01 Epub Date: 2022-07-08 DOI: 10.2217/pme-2021-0157

Wenting Meng, Wenjie Zhang, Shuangyu Yang, Xia Dou, Yuanwei Liu, Haiyue Li, Jianfeng Liu, Tianbo Jin, Bin Li

{"title":"Analysis of pharmacogenomic very important pharmacogenomic variants: CYP3A5, ACE, PTGS2 and NAT2 genes in Chinese Bai population.","authors":"Wenting Meng, Wenjie Zhang, Shuangyu Yang, Xia Dou, Yuanwei Liu, Haiyue Li, Jianfeng Liu, Tianbo Jin, Bin Li","doi":"10.2217/pme-2021-0157","DOIUrl":"https://doi.org/10.2217/pme-2021-0157","url":null,"abstract":"Aim: Our study aimed to screen the genotype frequencies of very important pharmacogenomic (VIP) mutations and identify their differences between Bai and other populations. Materials & methods: We selected 66 VIP variants from PharmGKB (www.pharmgkb.org/) for genotyping. χ2 test was used to identify differences in loci between these populations and FST values of Bai and the other 26 populations were analyzed. Results: Our study showed that the frequencies of SNPs of CYP3A5, ACE, PTGS2 and NAT2 differed significantly from those of the other 26 populations. At the same time, we found that some VIP variants may affect the metabolism of drugs and the genetic relationship between the Bai population and East Asian populations was found to be the closest. Conclusion: By comparing the genotype frequencies of different populations, the loci with significant differences were identified and discussed, providing a theoretical basis for individualized drug use in the Bai ethnic population.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 5","pages":"403-410"},"PeriodicalIF":2.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40570607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A sociogenomic paradigm to replace the racial paradigm. 用社会基因组学范式来取代种族范式。

IF 2.3 4区医学

Personalized medicine Pub Date : 2022-09-01 Epub Date: 2022-06-27 DOI: 10.2217/pme-2021-0141

Sajith Matthews, Phillip D Levy

引用次数: 0

The frequency of major CYP2C19 genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups. 亚裔、夏威夷原住民和太平洋岛民亚群妇女中主要 CYP2C19 基因多态性的频率。

IF 2.3 4区医学

Personalized medicine Pub Date : 2022-07-01 Epub Date: 2022-06-24 DOI: 10.2217/pme-2021-0175

Khalifa Y Alrajeh, Youssef M Roman

{"title":"The frequency of major CYP2C19 genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups.","authors":"Khalifa Y Alrajeh, Youssef M Roman","doi":"10.2217/pme-2021-0175","DOIUrl":"10.2217/pme-2021-0175","url":null,"abstract":"Aim: Prevalence of clinically actionable genetic variants of CYP2C19 is lacking in specific population subgroups. This study aims to assess the frequencies of CYP2C19*2, *3, and *17 in Asian, Native Hawaiian and Pacific Islander (NHPI) population subgroups compared with Europeans. Patients & methods: The study included repository DNA samples of 1064 women, 18 years or older, who self-reported as Filipino, Korean, Japanese, Native Hawaiian, Marshallese and Samoan. Results: The overall frequencies of CYP2C19*2 (25-36%) and CYP2C19*3 (2.5-10%) were significantly higher in all our subgroups than in Europeans (15 and 0.02%, respectively). The overall frequency of CYP2C19*17 was significantly lower in all our subgroups (1-6%) than in Europeans (21.7%). Conclusion: This is the first report on the frequencies of CYP2C19*2, *3, and *17 in women of Asian and NHPI descent with distinct population subgroup differences. Differential allele frequencies of CYP2C19 among population subgroups underscore the importance of increasing racial and ethnic diversity in pharmacogenetic research.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 4","pages":"327-339"},"PeriodicalIF":2.3,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318053/pdf/pme-19-327.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10078819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Personalized medicine in Nepal: current scenario and challenges. 尼泊尔的个体化医疗:现状和挑战。

IF 2.3 4区医学

Personalized medicine Pub Date : 2022-06-17 DOI: 10.2217/pme-2022-0002

Yunima Sapkota, Soniya Dulal, P. Gyawali, Ajnish Ghimire, Prabakaran Shankar

引用次数: 0

A novel epigenetic biomarker, plasma miR-138-5p gene promoter-methylated DNA, for colorectal cancer diagnosis. 一种新的表观遗传生物标志物，血浆miR-138-5p基因启动子甲基化DNA，用于结直肠癌诊断。

IF 2.3 4区医学

Personalized medicine Pub Date : 2022-06-17 DOI: 10.2217/pme-2021-0095

Masoud Asefi, M. Saidijam, Nayebali Rezvani, A. Soltanian, A. Khalilian, Ali Mahdavinezhad

引用次数: 1

Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls. 林奇综合征结直肠患者的微卫星不稳定性测试：从病例报告中吸取的教训以及如何避免此类陷阱。

IF 2.3 4区医学

Personalized medicine Pub Date : 2022-06-16 DOI: 10.2217/pme-2021-0128

S. Adeleke, Aidan Haslam, A. Choy, S. Diaz-Cano, J. Galante, C. Mikropoulos, S. Boussios

引用次数: 25

An international genomics health workforce education priorities assessment. 国际基因组学卫生人力教育重点评估。

IF 2.3 4区医学

Personalized medicine Pub Date : 2022-06-16 DOI: 10.2217/pme-2021-0094

D. Johnson, V. Dissanayake, B. Korf, Meredith Towery, R. Haspel

引用次数: 2

Alignment of health plan coverage policies for somatic multigene panel testing with clinical guidelines in select solid tumors. 选定实体瘤的躯体多基因面板检测与临床指南的健康计划覆盖政策的一致性

IF 2.3 4区医学

Personalized medicine Pub Date : 2022-05-01 Epub Date: 2022-02-04 DOI: 10.2217/pme-2021-0174

William B Wong, Daniele Anina, Chia-Wei Lin, Devon V Adams

{"title":"Alignment of health plan coverage policies for somatic multigene panel testing with clinical guidelines in select solid tumors.","authors":"William B Wong, Daniele Anina, Chia-Wei Lin, Devon V Adams","doi":"10.2217/pme-2021-0174","DOIUrl":"https://doi.org/10.2217/pme-2021-0174","url":null,"abstract":"Aim: Commercial plan coverage policies for multigene panel tests may vary and could result in geographic variation in coverage due to the fragmented nature of the commercial insurance market. This study aimed to characterize the alignment of multigene panel tests coverage policies to that of clinical guidelines, overall and by state. Materials & methods: We reviewed NCCN Guidelines® for four tumors. Public coverage policies were identified via web search. Payer policies included those with the largest or second largest number of commercial lives in each state. Policies were classified as 'more restrictive' or 'consistent' with the guidelines. Results: Of 38 plans/policies reviewed, 71% were classified as 'more restrictive' than the guidelines, with variation in the number of commercial lives by state. Among these, 52% restricted on panel size and 63% restricted in all or select tumors. Conclusion: Most coverage policies were more restrictive. Clinical guideline clarity and state policies may improve alignment to guidelines and geographic variations.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 3","pages":"171-180"},"PeriodicalIF":2.3,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39750516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Association of PON-1 polymorphism with susceptibility to and severity of ischemic stroke in the Chinese population. PON-1多态性与中国人群缺血性卒中易感性和严重程度的关系

IF 2.3 4区医学

Personalized medicine Pub Date : 2022-05-01 Epub Date: 2022-01-31 DOI: 10.2217/pme-2021-0133

Jianmin Huang, Yanfang Yun, Haiyan Chen, Guixin Yang, Yongming Jiang, Yaoxin Pan, Shengshan Yuan, Jianjun Huang, Li Su, Yingning Wu, Dong Lu, Anding Xu, Xuebin Li

引用次数: 3